Exploration of residual disease in stem cell products from mantle cell lymphoma using next-generation sequencing-Reference-Cited by-同舟云学术

Exploration of residual disease in stem cell products from mantle cell lymphoma using next-generation sequencing

Published:2022 Issue: Volume:18 Page:100341
ISSN:2213-0489
Container-title:Leukemia Research Reports
language:en
Short-container-title:Leukemia Research Reports

Author:

Elkjær Lea Amalia Lind,Cédile Oriane,Hansen Marcus Høy^ORCID,Nielsen Christian,Møller Michael Boe,Abildgaard Niels,Haaber Jacob,Nyvold Charlotte Guldborg^ORCID

Publisher

Elsevier BV

Subject

Oncology,Hematology

Reference17 articles.

1. Mantle Cell Lymphoma, Minimal residual disease in mantle cell lymphoma: are we ready for a personalized treatment approach?;Ferrero;Haematologica,2017

2. Minimal residual disease and survival outcomes in patients with mantle cell lymphoma: a systematic review and meta-analysis;Zhou;J. Cancer,2021

3. Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936;van Dongen;Leukemia,2003

4. Next-generation sequencing and real-time quantitative PCR for minimal residual disease detection in B-cell disorders;Ladetto;Leukemia,2014

5. Next-generation sequencing of immunoglobulin gene rearrangements for clonality assessment: a technical feasibility study by EuroClonality-NGS;Scheijen;Leukemia,2019

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. SWIGH-SCORE: A translational light-weight approach in computational detection of rearranged immunoglobulin heavy chain to be used in monoclonal lymphoproliferative disorders;MethodsX;2024-06